Amanta Healthcare, a dynamic pharmaceutical company, specializes in the development, manufacturing, and marketing of a wide range of sterile liquid products. Using advanced technologies like Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Molding (ISBM), the company produces both large and small volume parenteral (LVPs & SVPs), as well as medical devices. Their diverse product portfolio, marketed under their own brands in India and exported to various countries including Africa, Latin America, and the UK, spans six key therapeutic segments.

The company operates through three strategic business units: national sales, international sales, and product partnering, where they manufacture products for other pharmaceutical companies. With a robust portfolio of over 45 generic products and registrations in 19 countries, the company maintains a strong compliance record. Led by an experienced management team, their state-of-the-art manufacturing facility in Gujarat, India, holds multiple GMP certifications, ensuring high-quality production across their product lines.

For the year/period ended (Rs. in Cr.)

For year/ period ended ( in Cr.)

• Well-established manufacturer of pharmaceutical formulations with a diverse product portfolio and diverse market.
• Large manufacturing capabilities
• Wide Domestic and International Marketing Network.
• Experienced management team supported by a large, diverse and skilled workforce.

The Company AMANTA HEALTHCARE IPO proposes to utilise the Net Proceeds from the Issue towards the following objects:

• Funding capital expenditure requirements for civil construction work and towards purchase of equipment, plant and machinery for setting up new manufacturing line of SteriPort at Hariyala, Kheda, Gujarat (₹ 70 Cr.)
• Funding capital expenditure requirements towards civil construction work, purchase of equipment, plant and machinery for setting up new manufacturing line for SVP at Hariyala, Kheda, Gujarat (₹ 13 Cr.)
• General corporate purposes.

At the upper band of IPO ₹ 126, the stock is valued at 46.59 P/E multiple. Hence, well-informed investors subscribe for medium to long term perspective.